OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
OPKO Health (Nasdaq: OPK) said its management team will participate in the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
OPKO Health (Nasdaq: OPK) said its management team will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, held January 12-15, 2026. Management will host one-on-one investor meetings and take part in a fireside chat on Wednesday, January 14, 2026 at 1:30 p.m. PT. The fireside chat will be webcast live and available for replay in the Investors section of OPKO Health's website.
Details
News Market Reaction – OPK
On Jan 7, the first trading day after this news, OPK closed 3.03% above the previous close.
Data tracked by StockTitan Argus for the Jan 7 session.
Key Figures
- JPM conference dates
- January 12–15, 2026
- 44th Annual J.P. Morgan Healthcare Conference participation
- Q3 2025 revenue
- $151.7M
- Quarter ended September 30, 2025; down from $173.6M prior year
- Q3 2025 operating income
- $48.1M
- Supported by gain on BioReference oncology sale
- Q3 2025 net income
- $21.6M
- Quarterly net income; basic EPS $0.03
- Cash & equivalents
- $415.2M
- Cash, cash equivalents and current restricted cash as of Q3 2025
- Total liabilities
- $690.0M
- Total liabilities reported in Q3 2025 10-Q
- Labcorp oncology consideration
- $192.5M
- Total consideration for BioReference oncology diagnostics sale
- Foreign tax assessment
- $246M
- Approximate tax assessment disclosed with $9.9M accrual
Historical Context
-
Piper Sandler healthcare conference attendance and investor meetings announcement.
-
Q3 2025 results with profit supported by oncology asset sale to Labcorp.
-
ModeX collaboration with Regeneron using MSTAR platform and milestone economics.
-
First patient dosed in Phase 1/2a trial of MDX2004 for advanced cancers.
-
Scheduling notice for Q3 2025 financial results release and conference call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 44th Annual J.P. Morgan Healthcare Conference, being held January 12-15, 2026, at the Westin St. Francis Hotel in San Francisco. Management will be hosting one-on-one meetings with investors and will be participating in a fireside chat on Wednesday, January 14th at 1:30 p.m. Pacific time.
The fireside chat will be webcast live and available for replay in the Investors section of OPKO Health’s website here.
About OPKO Health
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.
Contacts:
Alliance Advisors IR
Yvonne Briggs, 310-691-7100
ybriggs@allianceadvisors.com
or
Bruce Voss, 310-691-7100
bvoss@allianceadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.